- Report
- January 2024
- 285 Pages
Global
From €9115EUR$9,500USD£7,882GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €10550EUR$10,995USD£9,122GBP
- Report
- June 2018
- 16 Pages
Global
From €9595EUR$10,000USD£8,297GBP
- Report
- April 2021
- 127 Pages
Global
From €10550EUR$10,995USD£9,122GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €959EUR$1,000USD£830GBP
Azilect is a brand of Central Nervous System (CNS) drugs used to treat Parkinson's disease. It is a monoamine oxidase type B (MAO-B) inhibitor, which works by blocking the breakdown of dopamine in the brain. This helps to reduce the symptoms of Parkinson's, such as tremors, stiffness, and difficulty with movement. Azilect is typically prescribed in combination with other medications, such as levodopa, to maximize its effectiveness.
The Azilect market is a growing segment of the CNS drug market, with a focus on treating Parkinson's disease. It is a highly competitive market, with a number of different companies offering their own versions of the drug. Companies in the Azilect market include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more
